ARTHEx pharma is a spin-off company from the University of Valencia focused on the development of Antisense RNA treatments for genetic diseases. The founders of the company are Dr. Beatriz Llamusí and Dr. Ruben Artero. The first product will be the development of a new drug (small molecule) addressed to the treatment of myotonic dystrophy (DM). DM is the most common muscle dystrophy in adults and it is a highly disabling disease with symptoms involving the skeletal musculature, the heart, and the nervous system. Thus, ARTHEx is a company that aims to develop a treatment against this disease based on microRNA inhibitors.
The business model proposed is based on an open innovation model in which the biotechnology company develops the products until phase 2 (efficacy), and then licenses them to pharmaceutical multinationals with the capacity to complete the development studies more advanced and its commercialization
The business model proposed is based on an open innovation model in which the biotechnology company develops the products until phase 2 (efficacy), and then licenses them to pharmaceutical multinationals with the capacity to complete the development studies more advanced and its commercialization
Location: Spain
Employees: 11-50
Total raised: $138.32M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 14.05.2023 | Hadean Ven... | hadeanvent... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 22.09.2025 | Series B | $87M | Sound Biov... |
| 11.05.2023 | Series B | $46.37M | European I... |
| 24.07.2020 | - | $4.95M | Advent Fra... |
Mentions in press and media 19
| Date | Title | Description |
| 22.09.2025 | ARTHEx Biotech: Series B Round Upsized To $87 Million For Myotonic Dystrophy Treatment Development | ARTHEx Biotech, a biotechnology company in the clinical stage of development, has recently made a significant announcement regarding its financing efforts. The company focuses on creating targeted RNA medicines, particularly for rare geneti... |
| 21.12.2023 | Hadean Ventures announces oversubscribed final close of Hadean Capital II | Hadean Ventures announces oversubscribed final close of Hadean Capital II – a fund dedicated to investments in life science start-ups across Europe Oslo, 21 December 2023. Hadean Ventures announced today the final close of Hadean Capital I... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 19.08.2023 | Revolutionizing Biotechnology in Spain: Unveiling 15 Innovative Startups | Embark on a journey through Spain’s thriving biotechnology landscape, where innovation intersects with life science. Join us as we delve into the realm of Biotech and uncover 15 startups that are reshaping industries, advancing healthcare, ... |
| 11.05.2023 | Arthex Biotech closes a €42M Series B financing round | EIT Health-supported start-up, Arthex Biotech, has successfully closed a €42 million Series B financing round. Prior to attracting these funds, the Valencia-based clinical-stage biotech start-up received an EIC accelerator grant, having bee... |
| 04.05.2023 | ARTHEx Biotech announces Closing of €42M Series B round led by Columbus. EIC), Hadean, Sound Bioventures, Invivo, AdBio and CDTI also participated | 04/05/2023 Nota de prensa ARTHEX BIOTECH ANNOUNCES CLOSING OF €42M SERIES B ROUND LED BY COLUMBUS. EIC), HADEAN, SOUND BIOVENTURES, INVIVO, ADBIO AND CDTI ALSO PARTICIPATED ARTHEx Biotech S.L., a clinical-stage biotechnology company focu... |
| 03.05.2023 | ARTHEx Biotech Announces Closing of €42 M Series B Financing | ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) The ArthemiRTM trial, a Phase I-IIa study of ATX-01 in DM1, is expected to initiate in 2H2023 Round le... |
| 03.05.2023 | ARTHEx Biotech Closes €42M Series B Financing | ARTHEx Biotech, a Valencia, Spain-based clinical-stage biotechnology company, raised €42M in Series B funding. The round was led by Columbus Venture Partners, with participation from new investors, the European Innovation Council (EIC), Had... |
| 10.11.2022 | Three EIT Health Catapult alumni receive EIC grants | A new wave of deep tech start-ups will receive accelerator grants and equity investments from the European Innovation Council (EIC). The European Commission selected 75 innovative start-ups after this year’s second EIC Accelerator cut-off. ... |
| 06.12.2021 | 21 start-ups reach EIT Health Catapult Final | Twenty-one start-ups from across Europe have secured their places at the EIT Health Catapult Final. The finalists represent the most promising European start-ups across biotech, medtech and digital health. The EIT Health Catapult, currentl... |
Show more